AzTrials
AzTrials

COPDMUKROBSNCT05480163

Acoustic and Volumetric Measurements in Order to Objectify Bronchial Congestion in Patients With Obstructive Respiratory Pathologies Within the Framework of Their Management in Respiratory Physiotherapy for Decongestion

A study testing Measurement records in people with COPD, run by Association des Réseaux Bronchiolite at 2 sites in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease defined by permanent airway obstruction. In this disease, a large part of the muscular work is taken up by breathing (fight against bronchial, parietal or fibrous resistances of the pulmonary tissue, reduction of the exchange surface)… Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
COPD
What is being tested?
Measurement records
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
2 sitesFrance
Study dates
18 Jun 2022to Aug 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Control group
  • Patient with no known respiratory pathology and a normal forced expiratory volume at one second (FEV1) /FVC ratio normal for age and sex (chart).
  • COPD group
  • Patients diagnosed with COPD, post exacerbations and/or post hospitalisation with chronic congestion

Who cannot join

  • Control group
  • Smoker or former smoker (less than 6 years of cessation)
  • Prolonged or repeated exposure to gases, dusts, fumes, vapours in the context of professional activities
  • Respiratory pathology
  • Pacemaker or heart battery wearers
  • Cognitive disorders that do not allow for informed consent
Show all 25Show fewer
  • Prostheses or metallic materials (vascular clip, neuro-stimulator, insulin pump, various implants, etc.)
  • Chest pain context
  • Spinal orthopaedic disorders not compatible with the device (cypho scoliosis etc...)
  • Opposition of the patient
  • BMI >30
  • History of hospitalization for coronavirus
  • COPD group :
  • Refusal to transfer image rights
  • Haemoptysis
  • Pacemaker or heart battery wearers
  • Cognitive impairment that does not allow for informed consent
  • Prostheses or metallic devices (vascular clip, neuro-stimulator, insulin pump, various implants)
  • Presence of oppressive chest pain
  • Neurological pathologies (Parkinson's, etc.)
  • Paradoxical breathing
  • Spinal orthopaedic disorders not compatible with the device (cypho scoliosis etc...)
  • Opposition of the patient
  • BMI >30
  • History of hospitalization for coronavirus

Trial locations and contacts

2 sites in 1 country.

France2 sites, 2 recruiting
  • Physiotherapy practice of Mr TORRES

    Annecy

    Laurent TORRES

    Recruiting
  • Physiotherapy practice of Mr. Jean-Charles LAPORTE

    Paris

    Jean-Charles LAPORTE

    Recruiting

Other trials in France

About this study

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease defined by permanent airway obstruction. In this disease, a large part of the muscular work is taken up by breathing (fight against bronchial, parietal or fibrous resistances of the pulmonary tissue, reduction of the exchange surface), requiring a physiotherapeutic care.

Physiotherapy management of "respiratory rehabilitation" includes 4 items: respiratory therapy for decongestion, muscle strengthening, improvement of endurance and therapeutic education. In this context, the techniques of de-cluttering aim to decrease the hydrodynamic resistance of the bronchial tree. A systematic evaluation of the patient's condition is carried out by the practitioners to assess, at the time of the session, the bronchial congestion. In addition to their knowledge of the history of the patient they are following and the result of the oximetry measurement, practitioners use several indicators to assess the patient's bronchial congestion and define their therapeutic approach: cough, sputum, oximetry and peak expiratory flow, pulmonary auscultation. Sound expertise remains delicate: even the most educated human auditory system is not physiologically capable of detecting some of the relevant information. The current quantification criteria are therefore not very objective, depend on the practitioner's expertise and do not allow recommendations to be made on the conduct of the session during the follow-up of patients. Consequently, the objectification of bronchial congestion is clearly part of the process of improving management. In this context, the MUKROBS project seeks to objectify the bronchial congestion of COPD patients during their management by means of respiratory physiotherapy techniques of de-congestion by means of expiratory flow modulation techniques.

The Sybille device, designed, developed and validated in the framework of a previous project funded by the ANR VirtualChest, allows continuous, non-invasive and simultaneous measurements of sound and displacement information at specific points of the thoracic cage.

Read the detailed description

COPD is a chronic respiratory disease defined by permanent airway obstruction. Epidemiological data are scarce: the prevalence is difficult to estimate because of underdiagnosis and the difficultý to perform respiratory function tests (RFTs) in epidemiological studies. It is estimated at 7.5% in a population over 45 years of age, with the incidence appearing to stabilize in men and increase in women. Furthermore, in 2018, 25.4% of adult patients had daily tobacco use. In 2014, 81,600 individuals were on long-term disability (LTD) for chronic bronchitis without specifics. The 2017 report by the Directorate for Research, Studies, Evaluation and Statistics (DREES) on the health status of the population in France shows that: in 2013, approximately 19,000 deaths were related to COPD, 48% of which were due to the initial cause; the crude mortality rateś related to COPD were 96/100,000 adults aged 45 years or older in men and 41/100,000 in women ; in 2014, the annual number of hospitalizations for COPD exacerbation ranged from 100 000 to 160 000, depending on the indicator; crude hospitalization rates were 31/10 000 in men and 15.4/10 000 in women, with the highest rates (>20%) in the northern and eastern regions of France and in Reunion. Standardized hospitalization rates have increased́ since 2000, by 2% per year in men and 5% per year in women. The average direct costs of COPD increase with the level of severitý of the disease and rise on average from €7,628 per year for the least severe patients to €20,747 per year for patients on oxygen therapy.

In this condition, a large part of the muscular work is taken up by breathing (fight against bronchial, parietal or fibrous resistances of the lung tissue, decrease of the exchange surface), requiring physiotherapeutic management.

The physiotherapeutic treatment "respiratory rehabilitation", includes 4 items: respiratory physiotherapy for decongestion, muscular strengthening, improvement of endurance and therapeutic education. Within this framework, the techniques of de-cluttering are intended to decrease the hydrodynamic resistance of the bronchial tree. A systematic evaluation of the patient's condition is carried out by the practitioners to assess, at the time of the session, the bronchial congestion. In addition to their knowledge of the history of the patient they are following and the result of the oximetry measurement, practitioners rely on several indicators to assess the patient's bronchial congestion and define their therapeutic approach: cough, sputum, oximetry and peak expiratory flow, pulmonary auscultation which provides sound information, and a call maneuver which allows a subjective assessment of the volumes that can be mobilized thanks to haptic information.

Sound expertise remains delicate: even the most educated human auditory system is not physiologically capable of detecting some of the relevant information. Multiple pathological breath sounds are referenced in the literature, for which different classifications exist, based on their frequency characteristics, their sound waveforms and their durations.

As for the haptic evaluation of thoracic compliance, it also requires a strong experience of the practitioner.

The current quantification criteria are therefore not very objective, depend on the practitioner's expertise and do not allow recommendations on the conduct of the session during the follow-up of the patients. Therefore, the objectification of bronchial congestion is clearly part of the improvement of the management of KR (Assess, Anticipate, Prevent, Treat). The design of specific tools dedicated to the quantified monitoring of relevant parameters of the lung condition is of definite interest to achieve these objectives.

In this context, the MUKROBS project seeks to objectivize the bronchial congestion of COPD patients, during their management by respiratory physiotherapy techniques of de-congestion by means of modulation of the expiratory flow.

The Sybille device, designed, developed and validated in the framework of a previous project funded by the ANR VirtualChest, allows continuous, non-invasive and simultaneous measurements of sound and displacement information at specific points of the thoracic cage. The investigators will conduct a measurement campaign in the context of follow-up in private practice. The measurements will be analyzed with numerical methods specifically developed in order to achieve an automatic identification of pathological respiratory sounds. The investigators will also try to localize bronchial obstructions and to correlate them with respiratory volume variations measured before, during and after the management session.

Conditions
COPD
Being tested
Measurement records
Medical subject headings
Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Measurement recordsOther

    Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.

Study groups in NCT05480163
Study groupRoleWhat they receive
Measurement records in COPD patientsExperimental1. The subject is informed of the procedure, his or her rights, and the use of the data collected (including the video recording of the session) 2. Pre-session clinical assessment by the physiotherapist 3. Installation of the Sybille waistcoat on the patient 4. First measurement phase: Recording of spirometry parameters, acoustics, movements (thoracic volumetry) for forced vital capacity (FVC) and LVC manoeuvres. 5. Second phase of measurements: Treatment: the physiotherapist performs the session in the classical way. Recording of acoustic parameters, movements (thoracic volumetry). 6. Third phase of measurements: Recording of spirometry, acoustics and movement parameters (thoracic volumetry) for FVC and LVC manoeuvres. 7. Removal of measurement devices 8. Post session evaluation by the physiotherapist.
Receives: Other: Measurement records
Measurement records in control subjectOther1. The subject is informed of the procedure, his or her rights, and the use of the data collected (including the video recording of the session) 2. Clinical assessment by the physiotherapist The subject answers the questionnaire 3. Installation of the Sybille waistcoat on the patient 4. Measurement phase: Recording of spirometry, acoustics, movements (thoracic volumetry) for FVC and LVC manoeuvres. 5. Removal of measurement devices
Receives: Other: Measurement records

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Scoring of respiratory congestion

    Comparison of the scoring of respiratory congestion status assessed by expert physiotherapists and by the Sybille device.

    Measured: 75 minutes

Secondary outcomes (7)
  1. Respiratory volumes in COPD group

    Respiratory volumes, before and after decongestion manoeuvres, obtained by spirometer in the COPD group.

    Measured: 75 minutes

  2. Volumes calculated from the displacements

    The volumes calculated from the displacements recorded by the Sybille device of 8 points located on the rib cage, before, during and after the decongestion manoeuvres, in the COPD group.

    Measured: 75 minutes

  3. Respiratory volumes in control group

    Respiratory volumes obtained by the spirometer in the control group.

    Measured: 40 minutes

  4. Volumes calculated in control group

    The volumes calculated from the displacements recorded by the Sybille device of 8 points located on the rib cage, in the control group.

    Measured: 40 minutes

  5. Rates by type of breath sounds

    The rates by type of breath sounds before, during and after the de-cluttering manoeuvres from the sounds recorded by the Sybille device, in the COPD group.

    Measured: 75 minutes

  6. Haptic sensations and the number and type of pathological breath

    The haptic sensations and the number and type of pathological breath sounds recorded during auscultations by the expert physiotherapists, and which are recorded in a questionnaire, for the COPD group

    Measured: 75 minutes

  7. Practitioners' treatment strategies

    Practitioners' treatment strategies described by Flanagan's critical incident method, in the COPD group.

    Measured: 75 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2022
  2. Study start18 Jun 2022
  3. Primary completionJul 2023 (estimated)
  4. Study completionAug 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05480163
Sponsor's protocol ID
MUKROBS
Other IDs
2021-A02143-38
Acronym
MUKROBS
Status last verified
Jul 2022
First submitted
25 Jul 2022
Last updated
29 Jul 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Measurement records in people with COPD, run by Association des Réseaux Bronchiolite at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Didier EVENOU (0660946700 ext. +33, devenou@orange.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Scoring of respiratory congestion (time frame: 75 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in